“You can’t have your cake—or in this case, your rebates—and a vibrant market for biosimilar competition too,” said FDA Commissioner Scott Gottlieb, MD.
In a speech delivered this morning at America’s Health Insurance Plans (AHIP) National Health Policy Conference, Scott Gottlieb, MD, Commissioner of the FDA, said that biologics and biosimilars are “an area where I have some of my most significant concerns about the long-term impact of the pricing and rebating mischief,” and warned that “the rigged payment scheme might quite literally scare competition out of the market altogether. I fear that’s already happening.”
While Gottlieb noted that, as of January 2018, 60 biosimilars were enrolled in the FDA’s biosimilar development program—and the agency has received meeting requests to discuss biosimilars for 27 distinct reference biologics—“the economics of development are currently unstable; and the pipeline of biosimilar products that we hope for could be dramatically affected by the weakening of market incentives to bring these products to patients.”
Gottlieb called into question pharmacy benefit managers (PBMs), wholesalers, and pharmacies, saying that market concentration of among these businesses (3 PBMs control more than 66% of the market, the top 3 wholesalers more than 80%, and the top 5 pharmacies more than 50%) may be inhibiting competition. “Too often, we see situations where consolidated firms—the PBMs, the distributors, and the drug stores—team up with [payers]. They use their individual market power to effectively split some of the monopoly rents with large manufacturers and other intermediaries rather than passing on the saving garnered from competition to patients and employers,” said Gottlieb.
These practices that inhibit competition drive up costs and effectively penalize patients with high out-of-pocket costs “where the primary purpose is to help subsidize rebates paid to a long list of supply chain intermediaries.”
Although Gottlieb acknowledged that steep co-pays for patients who need expensive drugs may help bring down average insurance premiums, “sick people aren’t supposed to be subsidizing the healthy.” Emphasizing the fact that lower-cost generic drugs often have low or no co-pays for patients and can help reduce cost burdens and increase treatment adherence, Gottlieb said that “we’re living in a world where financial toxicity is a real concern for patients. And every member of the drug supply chain needs to take responsibility for addressing it.”
Gottlieb also pointed a finger at the lengthy patent litigation practices that he says may be delaying the marketing of 6 approved but unlaunched biosimilars in the United States, and he raised the specter of “pay for delay” tactics (whereby the developer of a follow-on product may agree with an innovator product sponsor not to launch an approved follow-on until after an exclusivity period expires in exchange for monetary payment).
“The crux of these pay for delay schemes are also taking root in the biologics market,” explained Gottlieb, adding that, “Except this time, in these biosimilar pacts, the tactics are dressed in the guise of rebates and contracting provisions between manufacturers and PBMs that discourage biosimilar market entry.”
Ultimately, payers will have to decide whether they want to continue to benefit from rebates and contracting and the short-term profits that they provide or to invest in a system that works better for all stakeholders. “You can’t have your cake—or in this case, your rebates—and a vibrant market for biosimilar competition too,” he said.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.